Bristol Myers Squibb
Opdivo
previously untreated Stage III or IV classical Hodgkin Lymphoma
Resolved
90days ago
FDA decision · Apr 8, 2026
What's at stake
The FDA's approval decision on Opdivo for previously untreated Stage III or IV classical Hodgkin Lymphoma is due Apr 8, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“Opdivo ® (nivolumab) December 11 The U.S. Food and Drug Administration (FDA) granted priority review to the supplemental Biologics License Application for Opdivo ... The FDA assigned a Prescription Drug User Fee Act goal date of April 8, 20”